Aclaris Therapeutics Inc (NASDAQ:ACRS): James E. Flynn’s Deerfield Management filed an amended 13D.
You can check out Deerfield Management’s latest holdings and filings here.
Please follow Deerfield Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Deerfield Management or update its stock holdings.
Follow James E. Flynn's Deerfield Management
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Deerfield Management Company||0||1,769,377||0||1,769,377||1,769,377||5.90%|
|Deerfield Special Situations Fund||0||57,416||0||57,416||57,416||0.19%|
|Deerfield International Master Fund||0||604,322||0||604,322||604,322||2.01%|
|James E. Flynn||0||1,769,377||0||1,769,377||1,769,377||5.90%|
Page 1 of 14 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
INFORMATION TO BE INCLUDED IN STATEMENTS
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS
PURSUANT TO RULE 13d-2(b)
(Amendment No. ) *
Aclaris Therapeutics, Inc.
(Name of Issuer)
(Title of Class of Securities)
September 29, 2017
(Date of Event Which Requires Filing of
Check the appropriate box to designate the
rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
(Page 1 of 11 Pages)
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).